Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
1988-9-15
|
| pubmed:abstractText |
In a randomized, double-blind, multicenter trial we compared the efficacy of a preparation of human IgG antibody to Escherichia coli J5 (J5-IVIG) with that of a standard IgG preparation (IVIG) for the treatment of gram-negative septic shock. At study entry, patients received a single intravenous dose of 200 mg/kg of body weight (maximal dose, 12 g) of either J5-IVIG or IVIG. Of the 100 patients randomized, 71 (30 receiving J5-IVIG and 41 receiving IVIG) had a documented gram-negative infection. Mortality from gram-negative septic shock was 50% (15 of 30) in J5-IVIG recipients and 49% (20 of 41) in IVIG recipients. In addition, treatment with J5-IVIG did not reduce the number of systemic complications of shock and did not delay the occurrence of death due to septic shock. Thus we conclude that J5-IVIG was not superior to IVIG in reducing mortality or in reversing gram-negative septic shock.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Aug
|
| pubmed:issn |
0022-1899
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
158
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
312-9
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:3136210-Adolescent,
pubmed-meshheading:3136210-Adult,
pubmed-meshheading:3136210-Aged,
pubmed-meshheading:3136210-Child,
pubmed-meshheading:3136210-Clinical Trials as Topic,
pubmed-meshheading:3136210-Double-Blind Method,
pubmed-meshheading:3136210-Escherichia coli,
pubmed-meshheading:3136210-Female,
pubmed-meshheading:3136210-Gram-Negative Bacteria,
pubmed-meshheading:3136210-Humans,
pubmed-meshheading:3136210-Immunization, Passive,
pubmed-meshheading:3136210-Immunoglobulin G,
pubmed-meshheading:3136210-Immunoglobulins, Intravenous,
pubmed-meshheading:3136210-Male,
pubmed-meshheading:3136210-Middle Aged,
pubmed-meshheading:3136210-Prospective Studies,
pubmed-meshheading:3136210-Random Allocation,
pubmed-meshheading:3136210-Sepsis,
pubmed-meshheading:3136210-Shock, Septic
|
| pubmed:year |
1988
|
| pubmed:articleTitle |
Treatment of gram-negative septic shock with human IgG antibody to Escherichia coli J5: a prospective, double-blind, randomized trial.
|
| pubmed:affiliation |
Department of Internal Medicine, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|